Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 2014

View Archived Issues

Novel method described for real-time analysis of single-molecule biological processes over time

Investigators identify novel exon 3 mutation in Shwachman-Bodian-Diamond Syndrome gene

BioMarin Pharmaceuticals presents new information on BMN-701 for Pompe's disease

Preliminary results reported from phase Ib study of rhASM

GL-ONC1 found safe and feasible in phase I trial in head and neck cancer

Argenta achieves milestone in antibacterial drug discovery collaboration with Antabio

Zocere licenses neuroprotectant technology for stroke and other brain trauma

Betagenon begins phase I studies of O-304

TXNIP as a novel therapeutic target for stroke-induced oxidative injury

Alcon initiates first-in-human study of LHA-510 for AMD

Foundation Fighting Blindness provides further support for ReNeuron's ReN-003

UCB and Sanofi collaborate in immune-mediated diseases

Caisson expands HEPtune partnership with Novo Nordisk

NeuroDerm begins enrollment in second phase II study of ND-0612

U.S. researchers report development of compositions for rare genetic disease

Roche prepares new cathepsin S and/or L inhibitors

Rexahn Pharmaceuticals reports data from phase I trial of Supinoxin in solid tumors

Roche researchers present novel SYK inhibitors

Sunshine Lake Pharma discloses new compounds for HBV infection

Aeras begins phase II trial of AERAS-404 vaccine for tuberculosis

USAN Council selects vepoloxamer as unique non-proprietary name for API in MST-188

FDA grants orphan drug status to Rebiotix's C. difficile infection treatment

Innate Pharma continues phase II trial of lirilumab in AML based on DSMB recommendation

Celsus Therapeutics outlines timeline for MRX-6 atopic dermatitis program

Chimerix's brincidofovir pilot trial to begin immediately

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...